|
|
| |
|
Product development
|
Medicago is currently developing a Virus-Like Particle ("VLP") vaccine candidate for H5N1 Avian Influenza.
VLPs have significant advantages over conventional vaccines as they are known to enhance immunity and therefore increase protection against disease. These particles are similar to the virus from which they were derived from; however they lack viral nucleic acid, which results in the best compromise between safety (not infectious) and efficacy (highly immunogenic).
Using its proprietary plant-based technology, Medicago has the ability to deliver a VLP vaccine for testing a month after the identification and reception of genetic sequences from the pandemic strain.
Medicago has initiated preclinical studies with its proprietary VLP against H5N1 Avian Influenza virus and is now accumulating data. It is expected results from this first study will be published in the Q4 2007.
|
|
|
